Stratagene to Pay $10.75M to Settle Third Wave PCR Patent Suit | GenomeWeb
NEW YORK (GenomeWeb News) - Stratagene has agreed to pay $10.75 million to Third Wave Technologies to settle a patent-infringement suit related to PCR technology, the companies said today.
 
The suit was originally filed in 2004 in the US District Court in Wisconsin and Stratagene later filed an appeal in the Federal Circuit in Washington, DC, following a judgment in Third Wave’s favor.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.